Enwei Pharmaceutical Co

Enwei Pharmaceutical Co EBIT per Employee

The EBIT per Employee of Enwei Pharmaceutical Co (301331.SZ) as of Oct 21, 2026 is 37,970.29 CNY. In the previous year, EBIT per Employee was 31,408.85 CNY — a change of 20.89% (higher).

EBIT per Employee

37,970.29CNY

YoY

20.89%

Last updated:

EBIT per Employee of Enwei Pharmaceutical Co is 2025 37,970.29 CNY. EBIT per Employee of Enwei Pharmaceutical Co was 2024 31,408.85 CNY. It decreases by 20.89% higher compared to the previous year.

The Enwei Pharmaceutical Co EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2019
71,954.19 CNY
Jan 1, 2020
78,004.86 CNY
Jan 1, 2021
74,790.20 CNY
Jan 1, 2022
50,692.79 CNY
Jan 1, 2023
57,265.11 CNY
Jan 1, 2024
31,408.85 CNY
Jan 1, 2025
37,970.29 CNY
The Enwei Pharmaceutical Co EBIT per Employee history
YEAREBIT per EmployeeYoY
37,970.29CNY+20.89%
31,408.85CNY-45.15%
57,265.11CNY+12.96%
50,692.79CNY-32.22%
74,790.20CNY-4.12%
78,004.86CNY+8.41%
71,954.19CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enwei Pharmaceutical Co Stock analysis

What does Enwei Pharmaceutical Co do? Enwei Pharmaceutical Co., Ltd. generates revenue through the research, development, production, and sales of proprietary Chinese and chemical medicines. The company's main products include Jieeryin lotion, Jieeryin ointment, Jieeryin effervescent tablets, Shanmai Jianpi oral liquid, Qingjing capsules, and Danxiong Tongmai granules, which are primarily sold via direct sales and e-commerce channels. Its focus on gynecological products, pediatric medicines, and respiratory medicines targets domestic consumers seeking specialized healthcare solutions. The firm's domestic market strategy emphasizes direct customer engagement and online sales to reach its target segments. The company's product portfolio is tailored to specific health needs, with Jieeryin products addressing gynecological concerns, Shanmai Jianpi oral liquid supporting digestive health, Qingjing capsules for gynecological treatments, and Danxiong Tongmai granules targeting cardiovascular health. These offerings are distributed through direct sales teams and e-commerce platforms, aligning with the domestic market's preference for accessible healthcare products. Enwei's domestic focus ensures that its products meet local regulatory standards and consumer demands. Enwei Pharmaceutical's revenue streams are driven by the consistent demand for its specialized medicine categories, particularly in gynecology, pediatrics, and respiratory care. The firm's domestic market presence allows it to build strong relationships with healthcare providers and end-users, facilitating repeat purchases and brand loyalty. By concentrating on these key therapeutic areas, Enwei effectively serves its core customer segments without expanding into international markets. Enwei Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enwei Pharmaceutical Co stock

EBIT per Employee of Enwei Pharmaceutical Co is 37,970.29 CNY in 2025.

EBIT per Employee of Enwei Pharmaceutical Co changed from 31,408.85 CNY to 37,970.29 CNY, representing a 20.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Enwei Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Enwei Pharmaceutical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Enwei Pharmaceutical Co

All Key Metrics — Enwei Pharmaceutical Co